Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas

Sponsor

Children's Oncology Group (Other)

Overall Status

Completed

CT.gov ID

NCT01567046

Collaborator

National Cancer Institute (NCI) (NIH)

Enrollment

Location

Study Details

Study Description

Brief Summary

This research trial studies genes in tissue samples from younger and adolescent patients with soft tissue sarcomas. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer

Condition or Disease	Intervention/Treatment	Phase
Childhood Alveolar Soft-part Sarcoma Childhood Angiosarcoma Childhood Desmoplastic Small Round Cell Tumor Childhood Epithelioid Sarcoma Childhood Fibrosarcoma Childhood Leiomyosarcoma Childhood Liposarcoma Childhood Malignant Mesenchymoma Childhood Neurofibrosarcoma Childhood Synovial Sarcoma Chordoma Desmoid Tumor Metastatic Childhood Soft Tissue Sarcoma Nonmetastatic Childhood Soft Tissue Sarcoma Recurrent Childhood Soft Tissue Sarcoma	Other: laboratory biomarker analysis

Detailed Description

Study Subtype: Ancillary/Correlative Observational Study Model: Cohort Time Perspective:

Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Tissue Study Population Description: Existing NRSTS samples from the COG D9902/ARST0332 studies Sampling Method: Non-Probability Sample

OBJECTIVES:

To determine the frequency with which actionable mutations are found in archived non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) tumor specimens using mass spectrometry (MS) analysis of tumor-derived deoxyribonucleic acid (DNA).

OUTLINE:

Archived DNA tissue samples are analyzed for frequency of genetic mutations, including single nucleotide polymorphisms (SNPs), single nucleotide variants (SNVs), and small deletions and/or insertions, by polymerase chain reaction (PCR) and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.

Study Design

Study Type:

Observational

Actual Enrollment :

70 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Observational - Potentially Actionable Mutations in Archived Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)

Study Start Date :

May 1, 2016

Actual Primary Completion Date :

May 1, 2016

Actual Study Completion Date :

May 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Correlative studies Archived DNA tissue samples are analyzed for frequency of genetic mutations, including SNPs, SNVs, and small deletions and/or insertions, by PCR and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.	Other: laboratory biomarker analysis Correlative studies

Arm

Intervention/Treatment

Correlative studies

Archived DNA tissue samples are analyzed for frequency of genetic mutations, including SNPs, SNVs, and small deletions and/or insertions, by PCR and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.

Other: laboratory biomarker analysis

Correlative studies

Outcome Measures

Primary Outcome Measures

Frequency of individual mutated genes in patients with NRSTS [Up to 1 month]
Genetic changes that are most common and likely to have the greatest therapeutic impact [Up to 1 month]

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A to 30 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Archived non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) tumor-derived DNA
Synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), soft tissue sarcoma not otherwise specified (NOS), or other less common pediatric NRSTS
Formalin-fixed, paraffin-embedded (FFPE) tissue from patients enrolled on:
COG-D9902 Soft Tissue Sarcoma (STS) Biology and Banking Protocol
COG-ARST0332 A Risk-Based Treatment for Pediatric NRSTS Study
See Disease Characteristics